Cannabis Report
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 7/19/2018 10:12:22 AM - Followers: 154 - Board type: Free - Posts Today: 3

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.





Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#7033  Sticky Note Biggest and Best Aurinia Presentation to date (163 pages) moosedogger 05/07/18 09:48:57 AM
#7299   I am not invested in AUPH for any zzaatt 07/19/18 10:12:21 AM
#7298 LivingTheDream 07/19/18 09:24:33 AM
#7297   Cost of AUPH's medication might also be a north40000 07/19/18 01:36:16 AM
#7296   I think AUPH is poised to be ready zzaatt 07/18/18 10:57:53 PM
#7295   I think this new approach by Oyster Point ScifiSailor 07/18/18 03:59:12 PM
#7294   indeed NOT cervelo 07/17/18 02:17:07 PM
#7293   I thought these days of being brutalized were over............ biotech_researcher 07/16/18 03:42:11 PM
#7292   A different DES approach- what do you think? moosedogger 07/16/18 09:45:50 AM
#7291   "Here's Why Aurinia Pharmaceuticals Inc. Gained 32.2% in moosedogger 07/16/18 08:51:55 AM
#7290   Rick, your post worked!! biotech_researcher 07/13/18 03:51:34 PM
#7289   It just takes a couple of days to Maciste 07/13/18 03:28:49 PM
#7288   I had the same amount in ARIA. heldnova 07/13/18 03:26:40 PM
#7287   Wow Nova, you have a very sizable investment Jesspro 07/13/18 02:59:48 PM
#7286   Just when I say AUPH doesn't move with heldnova 07/13/18 02:23:45 PM
#7285   BR take a look at NTRP up $1.18 heldnova 07/13/18 11:48:40 AM
#7283   Well all of this good news explains the Maciste 07/12/18 11:05:35 AM
#7282   That’s great news! Hotrodder1 07/12/18 09:43:45 AM
#7281   Cantor Fitzgerald set a $16.00 target price on biotech_researcher 07/12/18 08:08:37 AM
#7280   BR, thanks for sharing... Jesspro 07/11/18 07:07:21 PM
#7279   Aurinia Initiates Phase 2 Clinical Trial for Voclosporin biotech_researcher 07/11/18 04:43:40 PM
#7278   We have been at 210 for some time tiv111 07/10/18 06:03:50 PM
#7277   Update: 210 sites LivingTheDream 07/10/18 02:29:51 PM
#7276   Wake me up when it reaches 10. somerssalt 07/09/18 12:37:00 PM
#7275   Anybody still here? No interest? biotech_researcher 07/09/18 10:52:03 AM
#7273   Suspended animation now..... biotech_researcher 07/03/18 09:52:32 AM
#7272   Apparently, Glickman did a little celebratory activity after biotech_researcher 06/27/18 07:37:55 PM
#7271   Didn't crash through the trend line so still LivingTheDream 06/26/18 11:32:34 AM
#7270   Maybe Duggan is buying more AKAO........really interesting day moosedogger 06/26/18 11:10:39 AM
#7269   Ugly.... biotech_researcher 06/26/18 11:03:27 AM
#7268   Aurinia Initiates Clinical Trials Broadening the Development of biotech_researcher 06/25/18 07:33:00 AM
#7267 Top Stock Picks 06/24/18 09:44:54 AM
#7266   “Is this in reference to Aurinia? I have biotech_researcher 06/22/18 08:29:48 PM
#7265   No buyers or trial troubles........Is this in reference zzaatt 06/22/18 03:43:33 PM
#7262   No buyers or trial troubles......... biotech_researcher 06/22/18 10:44:07 AM
#7261   Thanks BR. I can’t private message! Hotrodder1 06/20/18 03:39:38 PM
#7260   Late 2019 biotech_researcher 06/20/18 03:32:42 PM
#7259   Do we know when phase 3 results come out? Selain7 06/20/18 12:25:15 PM
#7258   Weak sister.... biotech_researcher 06/18/18 06:41:56 PM
#7257   It’s about to go gold! Hotrodder1 06/18/18 06:13:27 PM
#7256   Red?? Really? WTF Maciste 06/18/18 04:03:25 PM
#7255   Rick, good call. Something is mysterious about this company. biotech_researcher 06/18/18 03:55:01 PM
#7254   I agree the BOD other than Glickman not heldnova 06/18/18 03:21:12 PM
#7253   I think the fade is caused by the Maciste 06/18/18 03:07:27 PM
#7252   The afternoon fade.................. biotech_researcher 06/18/18 02:52:26 PM
#7251   Glickman is the only board member that is biotech_researcher 06/18/18 01:22:19 PM
#7250   Guessing this is the reason for the pop: moosedogger 06/18/18 12:56:13 PM
#7249   Thanks zz. Happy to help as this move biotech_researcher 06/18/18 10:30:14 AM
#7248   You were right!!! zzaatt 06/18/18 10:04:29 AM
#7247   Decisively above $6 it appears for the open.. biotech_researcher 06/18/18 08:48:17 AM
#7246   Indeed.... biotech_researcher 06/16/18 08:49:12 AM